Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

In this case, I was visiting my grandparents. And what I forgot was T-shirts. Yes, I forgot to pack an entire category of clothing. Not long after my arrival, I bought an emergency T-shirt from a ...

Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...

What do Amgen, Biogen, and Takeda have in common? Leaders of research and development at the three biopharma companies shared a stage Thursday at the STAT 2024 Summit in Boston and offered their ...

Strategic acquisitions and pipeline expansions remain central to future growth plans. Amgen revealed a positive third quarter of 2024, exceeding earnings expectations. Despite some challenges in ...

Amgen, a global biotechnology leader highlighting profound research and development capabilities and biomanufacturing, showcases its latest achievements in the field of innovative medicines under ...

The latest trading session saw Amgen (AMGN) ending at $325.09, denoting a +0.14% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.76%.

Nico Chen has given his Buy rating due to a combination of factors including Amgen’s consistent performance in launching blockbuster drugs and positive clinical trial data, as well as strategic ...

Amgen (NASDAQ:AMGN) is scheduled to announce Q3 earnings results on Wednesday, October 30th, after market close. Investors and analysts will be looking for updates on the mid-stage trial of Amgen ...

(RTTNews) - Amgen Inc. (AMGN) Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults with generalized myasthenia gravis, a rare ...